Email Alert | RSS    帮助

中国防痨杂志 ›› 2018, Vol. 40 ›› Issue (6): 593-598.doi: 10.3969/j.issn.1000-6621.2018.06.009

• 论著 • 上一篇    下一篇



  1. 102206 北京,中国疾病预防控制中心结核病预防控制中心
  • 收稿日期:2018-03-13 出版日期:2018-06-20 发布日期:2018-07-24
  • 基金资助:

Analysis of treatment outcomes and influencing factors of 208 multidrug-resistant pulmonary tuberculosis patients

Wei SU,Ren-zhong LI,Yun-zhou RUAN,Cai-hong XU,Ming-ting. CHEN()   

  1. National Center for Tuberculosis Control and Prevention,Chinese Centers for Disease Control and Prevention, Beijing 102206,China
  • Received:2018-03-13 Online:2018-06-20 Published:2018-07-24

摘要: 目的








关键词: 结核, 肺, 结核, 抗多种药物性, 治疗结果, 因素分析, 统计学

Abstract: Objective

To analyze the factors that affect the treatment outcomes of multidrug-resistant tuberculosis (MDR-TB) patients based on the free treatment of MDR-TB patients.


From 2009 to 2010, 208 multidrug-resistant pulmonary tuberculosis patients were enrolled as research subjects from Wuhan City, Hubei Province, Zhenjiang City, Jiangsu Province, and Liaocheng City, Shandong Province during the implementation of the Global Fund Project. A retrospective survey was conducted to analyze the outcomes of treatment and its influencing factors.


Of the 208 patients, 103 (49.5%) were successful, 47 (22.6%) were lost to follow-up, 32 (15.4%) failed and 26 (12.5%) died; 72.1%(150 cases) of patients were remained after 12 months of treatment and 61.1% (127 cases) of patients were remained after 18 months of treatment; patients lost from treatment were mainly due to self-discontinued (51.1%, 24/47) and working elsewhere (21.3%, 10/47); Age ≥60 years old (OR=5.964,95%CI=2.517-14.133), farmers (OR=2.871,95%CI=1.530-5.389), used second-line antituberculosis drugs (OR=2.158,95%CI=1.156-4.028) were the risk factors for successful treatment of MDR-TB.


Based on the free treatment for MDR-TB patients, the successful rate of treatment is not high, there is a high rate of tracking loss during treatment. The suggestion is that it is necessary to explore strategies to shorten the course of treatment and diagnostic time for MDR-TB and pay attention to the treatment and management of special groups such as the elderly and farmers as well as regulate the use of second-line anti-tuberculosis drugs.

Key words: Tuberculosis, pulmonary, Tuberculosis, multidrug-resistant, Treatment outcome, Factor analysis, statistics